Stem cell and other new biological therapies are target of major NIH contract to U of MN

November 17, 2003

MINNEAPOLIS / ST. PAUL (Nov. 17, 2003) -- The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), has awarded a $7.7 million contract to the University of Minnesota to collaborate with two other institutions on the production and testing of novel somatic (biological) cell therapies, including adult stem cells. Under the five-year contract, the University of Minnesota's Molecular and Cellular Therapeutics facility (MMCT) will work with Baylor College of Medicine's Center for Cell and Gene Therapy and the University of Pittsburgh's Cancer Institute.

The project is designed to aid researchers in bringing the basic science of new cellular therapies to human clinical trials, and eventually, to clinical practice--a process known as translational research. The biological therapies represented in the University of Minnesota contract include use of adult stem cells (in particular, multipotent adult progenitor cells, or MAPCs), expansion of umbilical cord blood (UCB) hematopoietic (blood) stem cells, tumor vaccines, and genetically modified immune system cells. In addition, the team will develop a post-doctoral training program in translational medicine and production of somatic cell therapies, in compliance with strict FDA guidelines.

"The potential is great for these therapies," said lead investigator John E. Wagner Jr., M.D., professor of pediatrics and Scientific Director of the Minnesota Molecular and Cellular Therapeutics (MMCT) Facility and of Clinical Research for the Blood and Bone Marrow Transplant Program and of the Stem Cell Institute at the University of Minnesota. "We had the infrastructure to produce the biological materials used in these therapies, and now we have the funding to make them readily available for innovative clinical trials. This funding is an example of how the NIH recognizes the importance of translational research, to help move basic science discoveries more rapidly to direct patient care and treatment."

The University is in the forefront of translational research, as evidenced by the existence of the MMCT facility and the future Translational Research Facility (TRF). Currently, the MMCT, a 36,000 square-foot facility on the St. Paul campus, will house much of the research. The facility provides support for the development of phase I and II clinical trials of advanced cell, tissue, and gene-based therapies by translating research lab technologies into clinically applicable biologic reagents. The programs in the MMCT provide the technical expertise, as well as the regulatory structure, to ensure that all FDA requirements are satisfied.

An example of the ongoing work, Wagner and his team are working on adult stem cells, which may be useful for treating a number of diseases, such as Parkinson's, stroke, diabetes, and heart disease. Researchers at the University of Minnesota Stem Cell Institute (SCI), led by Catherine M. Verfaillie, M.D., have shown that adult bone marrow-derived cells can differentiate into many types of cells, including liver, pancreas, and brain. These multipotent adult progenitor cells (MAPCs) are a major focus of potential stem cell treatments.

Wagner is also investigating the use of umbilical cord blood to treat children and adults with immune disorders, leukemia, tumors, lymphoma, anemias, metabolic disorders, and bone marrow failure. Umbilical cord blood contains stem cells that can be transplanted to produce all blood cells in the human body--red blood cells, white blood cells, and platelets--necessary for creating healthy bone marrow and immune system. "Developing methods to expand the number of stem cells is crucial for the application of umbilical cord blood transplantation in adults," said Wagner.

The team is also working on developing tumor vaccines, a project led by Jeffrey Miller, M.D. Currently, researchers at the University are developing a breast cancer vaccine that is created with a patient's own cancer cells. The vaccine is created by extracting proteins from a patient's breast tumor cells and attaching them to microscopic immunization beads. The vaccine is then injected back into the patient in an effort to trigger the patient's own immune system to destroy cancer cells. This contract with NHLBI will enable further research in tumor vaccines, including prostate, melanoma, and renal cancers.

While immune cells can act as cancer-killing cells, there are risks that these cells could attack the patient's healthy tissue as well. "Genetic modification with a 'suicide' gene provides an added level of safety," stated Wagner. If the cancer-killing cells cause undesirable effects, the cells can be destroyed by activating the 'suicide' gene with an antibiotic. This important research is being led by Paul Orchard, M.D.

"Overall, a key aspect of this multi-million dollar contract is the collaboration it will facilitate," said Wagner. "Instead of competing with each other, we will be pooling our resources and individual areas of expertise to translate cutting-edge basic laboratory studies into care. This will ultimately lead us to breakthrough therapies in the treatment of cancer, heart disease, diabetes, and more."

University of Minnesota

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to